Come si colloca il rapporto IDX di PS rispetto ai suoi colleghi?

IDX è costoso in base al suo rapporto Price-To-Sales ( 1.5 x) rispetto alla media dei peer ( 1.1 x).

Come si colloca il IDX's PS Ratio rispetto ad altre aziende del AU Healthcare settore?

IDX è costoso in base al suo rapporto Price-To-Sales ( 1.5 x) rispetto alla media del settore Australian Healthcare ( 1.5 x).

Qual è il IDX PS Ratio rispetto al suo Fair PS Ratio? Si tratta del PS Ratio atteso, tenendo conto delle previsioni di crescita degli utili, dei margini di profitto e di altri fattori di rischio della società.

IDX è costoso in base al suo rapporto Price-To-Sales ( 1.5 x) rispetto al rapporto equo Price-To-Sales stimato ( 1.2 x).

Qual è il prezzo equo di IDX se si considerano i suoi flussi di cassa futuri? Per questa stima utilizziamo un modello di Discounted Cash Flow.

IDX ( A$2.92 ) viene scambiato al di sotto della nostra stima del [[fair value]] ( A$18.51 )

Qual è la previsione a 12 mesi degli analisti e abbiamo una qualche fiducia statistica nell'obiettivo di prezzo del consenso?

Il prezzo obiettivo è inferiore del 20 % rispetto al prezzo attuale delle azioni.

Integral Diagnostics (ASX:IDX) - Prezzo delle azioni, notizie e analisi

IDX Panoramica delle azioni

IDX analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	4/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	1/6

Premi

Negoziato a 84.2% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 89.25% all'anno

Analisi del rischio

I pagamenti degli interessi non sono ben coperti dagli utili

Integral Diagnostics Limited Concorrenti

Australian Clinical Labs

ASX:ACL

AU$697.5m

Capitol Health

ASX:CAJ

AU$383.8m

Healius

ASX:HLS

AU$980.3m

Healthia

ASX:HLA

AU$252.1m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Integral Diagnostics
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$2.92
Massimo di 52 settimane	AU$3.20
Minimo di 52 settimane	AU$1.65
Beta	0.68
1Variazione di 1 mese	-7.59%
Variazione a 3 mesi	12.31%
Variazione di 1 anno	71.26%
3Variazione a 3 anni	-38.78%
Variazione a 5 anni	-19.78%
Variazione dall'IPO	59.56%

Notizie e aggiornamenti recenti

Recent updates

Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital

Feb 21

Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being

Nov 22

Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

Feb 20

These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively

Dec 14

Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?

May 26

Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year

Feb 28

Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Feb 25

Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why

Oct 29

Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?

Sep 13

An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued

Jun 04

Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?

May 14

Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?

May 03

We Think Integral Diagnostics (ASX:IDX) Can Stay On Top Of Its Debt

Apr 16

Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?

Mar 27

Is Integral Diagnostics Limited's (ASX:IDX) Stock's Recent Performance A Reflection Of Its Financial Health?

Mar 17

Integral Diagnostics Limited's (ASX:IDX) Intrinsic Value Is Potentially 46% Above Its Share Price

Feb 03

Here's What We Learned About The CEO Pay At Integral Diagnostics Limited (ASX:IDX)

Jan 24

Should You Use Integral Diagnostics's (ASX:IDX) Statutory Earnings To Analyse It?

Jan 14

Shareholders Of Integral Diagnostics (ASX:IDX) Must Be Happy With Their 201% Total Return

Jan 05

Is Integral Diagnostics (ASX:IDX) A Risky Investment?

Dec 26

At AU$4.30, Is It Time To Put Integral Diagnostics Limited (ASX:IDX) On Your Watch List?

Dec 17

What To Know Before Buying Integral Diagnostics Limited (ASX:IDX) For Its Dividend

Dec 08

Returns On Capital At Integral Diagnostics (ASX:IDX) Paint An Interesting Picture

Nov 29

Is Integral Diagnostics Limited's (ASX:IDX) Shareholder Ownership Skewed Towards Insiders?

Nov 19

Rendimenti per gli azionisti

	IDX	AU Healthcare	AU Mercato
7D	-1.7%	5.7%	0.9%
1Y	71.3%	7.1%	18.4%

Ritorno vs Industria: IDX ha superato il Australian Healthcare che ha restituito 7.1 % nell'ultimo anno.

Rendimento vs Mercato: IDX ha superato il mercato Australian che ha restituito 18.4 % nell'ultimo anno.

Volatilità dei prezzi

Is IDX's price volatile compared to industry and market?
IDX volatility
IDX Average Weekly Movement	3.8%
Healthcare Industry Average Movement	4.8%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.2%

Prezzo delle azioni stabile: IDX non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 4% ) di IDX è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1967	1,977	Ian Kadish	www.integraldiagnostics.com.au

Integral Diagnostics Limited, società di servizi sanitari, si occupa della fornitura di servizi di diagnostica per immagini a medici generici, specialisti e professionisti sanitari alleati e ai loro pazienti in Australia e Nuova Zelanda. Fornisce tomografia a emissione di positroni, risonanza magnetica e altri servizi di radiologia. L'azienda è stata fondata nel 1967 e ha sede a Melbourne, in Australia.

Integral Diagnostics Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Integral Diagnostics con la sua capitalizzazione di mercato?
IDX statistiche fondamentali
Capitalizzazione di mercato	AU$678.36m
Guadagni(TTM)	-AU$60.70m
Ricavi(TTM)	AU$469.70m

1.5x

Rapporto P/S

-11.3x

Rapporto P/E

IDX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
IDX Conto economico (TTM)
Ricavi	AU$469.70m
Costo del fatturato	AU$317.80m
Profitto lordo	AU$151.90m
Altre spese	AU$212.60m
Guadagni	-AU$60.70m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Feb 25, 2025

Utile per azione (EPS)	-0.26
Margine lordo	32.34%
Margine di profitto netto	-12.92%
Rapporto debito/patrimonio netto	72.8%

Come si è comportato IDX nel lungo periodo?

Vedi performance storica e confronto

Dividendi

2.0%

Rendimento attuale del dividendo

-22%

Rapporto di remunerazione

IDX Panoramica delle azioni

Premi

Analisi del rischio

Integral Diagnostics Limited Concorrenti

ASX:ACL

AU$697.5m

ASX:CAJ

AU$383.8m

ASX:HLS

AU$980.3m

ASX:HLA

AU$252.1m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Integral Diagnostics Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Price target increased by 7.7% to AU$2.93

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

First half dividend of AU$0.025 announced

First half 2024 earnings: EPS misses analyst expectations

Recent updates

Integral Diagnostics Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Price target increased by 7.7% to AU$2.93

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

First half dividend of AU$0.025 announced

First half 2024 earnings: EPS misses analyst expectations

Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital

Consensus EPS estimates fall by 12%

IDX™ Announces Appointment of Scott Paterson as Worldwide CFO

Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024

Integral Diagnostics Limited Announces Change of Company Secretary

Independent Non-Executive Director recently bought AU$258k worth of stock

Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023

Consensus EPS estimates fall by 11%

Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being

Price target decreased by 7.5% to AU$3.05

Consensus EPS estimates fall by 10%

Investor sentiment deteriorates as stock falls 27%

Integral Diagnostics Limited Appoints Toby Hall as Director

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023

Full year 2023 earnings: EPS misses analyst expectations

Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023

Consensus EPS estimates fall by 16%

Integral Diagnostics Limited Announces Board Changes

Investor sentiment deteriorates as stock falls 18%

Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

First half 2023 earnings released: EPS: AU$0.069 (vs AU$0.051 in 1H 2022)

Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023

Now 21% undervalued after recent price drop

Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023

Integral Diagnostics Limited to Report Fiscal Year 2023 Results on Aug 28, 2023

These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively

Independent Non-Executive Director recently bought AU$114k worth of stock

Consensus forecasts updated

Now 22% undervalued after recent price drop

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Year Ended June 30, 2022, Payable on October 5, 2022

Full year 2022 earnings released

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to AU$3.65

Integral Diagnostics Limited Announces Appointment of Andrew Fay as an Independent Non-Executive Director

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?

Now 21% undervalued after recent price drop

Integral Diagnostics Limited (ASX:IDX) ) agreed to acquire Exact Radiology Pty Ltd for NZD 33.3 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Exact Radiology Pty Ltd for approximately AUD 39 million.

Now 21% undervalued

Executive Director recently bought AU$70k worth of stock

Consensus forecasts updated

Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year

Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Integral Diagnostics Limited Announces the Distribution for the Six Months Ended December 31, 2021, Payable on April 4, 2022

Consensus forecasts updated

Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why

Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.12 in FY 2020)

An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued